ACCELERATING RESEARCH

Strategic investments in cutting-edge biomedical research and patient engagement to advance the pursuit of treatments and a cure for celiac disease.

Driving Innovation

iCureCeliac Patient Registry

iCureCeliac is the USA’s largest public patient registry for celiac disease.

iQualifyCeliac Trial Screening Tool

iQualifyCeliac is the only patient-driven celiac disease clinical trial and study recruitment screening tool.

Young Investigator Research Grant Award

Encouraging the brightest minds in research to focus on finding treatments and a cure for celiac disease.

Advancing Therapeutic Treatment Development

iCureCeliac empowers patients to share their medical information and experiences to shape the future of celiac disease research.

iQualifyCeliac screening tool speeds participation in clinical trials and studies to advance the development of better treatments and a cure for celiac disease.

Funding the Young Investigator Research Grant Award, medical education conferences at leading institutions, research studies, and technology innovation including the MedAboutData Hackathon for early diagnosis of celiac disease.

TOTAL REGISTRANTS in iCureCeliac
7,000

NUMBER OF CLINICAL TRIALS recruited for in 2018-2019
11

2018-2019 FUNDING OF RESEARCH AND CONFERENCES
$850,000

IMPACTING PATIENTS

6.5M VISITORS TO CELIAC.ORG annually

2,000 COMMUNITY FUNDRAISING PARTICIPANTS 2018-2019

3,000 ATTENDEES GLUTEN-FREE EXPO annually

PROMOTING EDUCATION

Outreach to patients and healthcare providers has improved the diagnostic rate for celiac disease. Focused investments continue to close the gap and end the needless suffering of millions.

Visitors to celiac.org
6.5M

Community Fundraising Participants 2018-2019
2,000

Attendees Gluten-Free Expo annually
3,000

EDUCATING PROVIDERS TO IMPROVE CARE

NASPGHAN Clinical Guide for Pediatric Celiac Disease assists physicians in the diagnosis and management of celiac disease.

Celiac Disease and Psychological Health Program partnership with Children’s National educates medical and mental health providers on diagnosing celiac disease and its psychological impact.

Celiac Disease Residency Training Program at the Keck School of Medicine of USC trains new physicians in the recognition and treatment of celiac disease.

Physicians educated since 2017
15,000

Providers educated since 2016
300

Residents educated since 2017
600

EXPANDING REACH IN 2019

House Appropriations Subcommittee testimony by CEO Marilyn G. Geller for dedicated National Institutes of Health (NIH) funding for celiac disease research.

Patient-Centered Outcomes Research Institute (PCORI) National Patient Engagement Advisory Panel appointment of Marilyn G. Geller, CEO.

NASPGHAN and Children’s National partnership to create the Celiac Disease Management Plan to standardize federally-sanctioned accommodations in US schools.

Giving Voice to the Celiac Community

The Patient Advocate Program prepares participants to engage in celiac disease research and public advocacy.

Collaboration with advocacy coalition partners on federal initiatives to support patient protections for autoimmune disease.

Partnered with Congressmen Tim Ryan and Tom Cole to introduce the Gluten in Medicine Disclosure Act for easier identification of gluten in prescription drugs.

Trained Participants since 2016
1,300

2018-2019 Executed Initiatives
12

2018-2019 Stakeholder Emails Sent to Congress
22,000

EFFECTIVE ADVOCACY

Committed to being the worldwide voice of the celiac community before key policy makers in Congress and federal research and regulatory agencies.

Gluten Free Expo

www.celiac.org

Celiac Disease and Psychological Health Program

Celiac Disease Residency Training Program

Celiac Disease Management Plan

The Patient Advocate Program

Gluten in Medicine Disclosure Act
### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$1,672,924</td>
</tr>
<tr>
<td>Contributions Receivable</td>
<td>$92,104</td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>$145,950</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$4,430</td>
</tr>
<tr>
<td>Investment in Partnership</td>
<td>$37,450</td>
</tr>
<tr>
<td>Deposits</td>
<td>$8,425</td>
</tr>
<tr>
<td>Property and Equipment</td>
<td>$119,761</td>
</tr>
</tbody>
</table>

**Total Assets** $2,081,044

### LIABILITIES

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable</td>
<td>$16,843</td>
</tr>
<tr>
<td>Accrued Vacation</td>
<td>$44,234</td>
</tr>
<tr>
<td>Unearned Revenue</td>
<td>$157,793</td>
</tr>
</tbody>
</table>

**Total Liabilities** $218,870

### NET ASSETS

<table>
<thead>
<tr>
<th>Type</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$1,862,174</td>
</tr>
</tbody>
</table>

**Total Liabilities and Net Assets** $2,081,044

### OPERATING SUPPORT

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and Grants</td>
<td>$1,030,976</td>
</tr>
<tr>
<td>Annual Meeting</td>
<td>$69,306</td>
</tr>
<tr>
<td>Gifts in Kind</td>
<td>$372,736</td>
</tr>
<tr>
<td>Sponsorships, Program Income and Special Events</td>
<td>$662,289</td>
</tr>
</tbody>
</table>

**Total Revenue** $2,135,307

### OPERATING EXPENSES

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Expenses</td>
<td>$1,318,016</td>
</tr>
<tr>
<td>Management and General</td>
<td>$66,430</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$50,334</td>
</tr>
</tbody>
</table>

**Total Expenses** $1,434,780

**Change in Net Assets** $700,527